Print Page  |  Close Window

Overview

Where the power of nature meets the logic of science for the betterment of health.
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and acquire early stage, ingredient technologies that are protected by intellectual property.... More »

Stock Quote
NASDAQ - CDXC
Price$3.70
Change (%) Stock is Down 0.12 (3.14%)
Volume325,314
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
06/27/17ChromaDex Appoints Harvard Medical School Professor of Neurology, Dr. Rudolph Tanzi, to the Scientific Advisory Board
Global Alzheimer’s Thought Leader to Assist in Exploring Potential for Nicotinamide Riboside in Brain and Neuronal Health IRVINE, Calif., June 27, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has appointed Dr.  Rudolph Tanzi, Vice-Chair of Neurology an... 
Printer Friendly Version
06/12/17ChromaDex announces an exclusive worldwide patent license and research agreement with The Scripps Research Institute to identify the potential role of NIAGEN® in treating breast cancer
IRVINE, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has signed a new, exclusive patent license and research agreement with The Scripps Research Institute (TSRI), gaining access to groundbreaking, pre-clinical discoveries by Dr. Brunie ... 
Printer Friendly Version
06/05/17ChromaDex Names World’s Leading Expert on Nicotinamide Riboside and NAD as Chief Scientific Advisor
Charles Brenner, PhD, an investigator on the forefront of metabolism research, to champion the advancement of NR and NAD boosting technologies IRVINE, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that Charles Brenner, PhD, the Roy J. Carver Ch... 
Printer Friendly Version
Upcoming EventsMore »

There are currently no events scheduled.

What's New
Download DocumentationSpecial Meeting – Proxy Statement
Download Documentation2017 Q1 Quarterly Report on Form 10Q
Download Documentation2017 Proxy Statement
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.